Loading
A phase 2 trial of Ubamatamab and REGN7075 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, now recruiting.
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT07154290 by Regeneron Pharmaceuticals, with 300 participants planned, started 2026-03-18 and due to reach its primary completion in 2030-06-10. Interventions recorded: Ubamatamab, Marlotamig and Sarilumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regeneron, Non-small-cell lung cancer and the tag pipeline.
Shares Regeneron and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/